Gore Receives Health Canada Approval for GORE® VIABAHN® Endoprosthesis Innovations, Treating Peripheral Vascular Disease

Longer and Lower Profile Options Now Available in Canada to Treat More Patient Anatomies

Flagstaff, Ariz. (February 4, 2015)—W. L. Gore & Associates (Gore) today announced that it has received approval from Health Canada for two innovations of the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface. The newly approved 25 cm long endoprosthesis and a lower profile delivery system gives Canadian physicians more options in treating patient anatomies.

The 25 cm GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface is the longest length stent-graft available, and can be used to treat long-segment peripheral arterial disease. The device is constructed with a durable, reinforced, biocompatible, expanded polytetrafluoroethylene (ePTFE) liner attached to an external nitinol stent structure. The flexibility of the GORE VIABAHN Endoprosthesis enables it to traverse tortuous areas and conform closely to the complex anatomy of the artery. The stent-graft features the addition of proprietary heparin-bonded technology. The end-point covalent bonding keeps heparin anchored to the endoprosthesis surface while the bioactive site remains free to interact with the blood.

“With patient outcomes as the top priority, the longer 25 cm GORE VIABAHN Endoprosthesis will lead to safer treatment and produce better patient results while being cost-effective and reduce procedure times,” said Andrew Benko, MD, University of Sherbrooke. “The addition of a lower profile Gore device creates safe treatment options for patients with challenging anatomies and will be ideal for contralateral work.”

The new lower profile GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface offers more options for less-invasive endovascular treatment. This next generation device enables a reduction in delivery profile to 6 Fr for 5 and 6 mm devices and 7 Fr for 7 and 8 mm devices and is delivered over a 0.018" or 0.014" guidewire.

“Gore Medical is committed to improving patient outcomes and we are happy to provide the latest innovations of the GORE VIABAHN Endoprosthesis to Canadian physicians,” said Ray Swinney, Business Unit Leader for the Gore Peripheral Interventional Business Unit.

ABOUT W. L. GORE & ASSOCIATES

At Gore, we have provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 35 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the US “100 Best Companies to Work For” lists since the rankings debuted in 1984.

 

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.